Multi-Centre Trial of Fresh vs. Frozen-and-Thawed HBT(Fecal Transplant)for Recurrent CDI
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal of this study is to determine the outcome of patients with recurrent CDI treated with fresh HBT versus frozen-and-thawed HBT in a randomized controlled trial. The specific objectives are to evaluate the safety of both types of HBT and to compare the clinical response, treatment failure and relapse rate in patients treated with fresh HBT compared to those treated with frozen-and-thawed HBT; also to assess the functional health and well-being of patients in each arm using a validated tool. The metagenomics will also be conducted from the stool samples collected from select patients from each arm: pre and post treatment and the matching donors. The metagenomics data will be used to determine the bacteria which may have contributed to the cure of CDI.
| Condition | Intervention | Phase |
|---|---|---|
|
Clostridium Difficile Infection |
Procedure: Fresh Human Biotherapy Procedure: Frozen-and-Thawed Human Biotherapy |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Prospective Randomized Multi-Centre Trial of Fresh vs. Frozen-and-Thawed Human Biotherapy (Fecal Transplant) for Recurrent Clostridium Difficile Infection |
- The evaluation of the safety of HBT [ Time Frame: 13 Weeks post HBT ] [ Designated as safety issue: Yes ]Assessment for adverse reactions in each study group by history, physical examination, blood work at baseline, day 12, week 5 and at completion (week 13) of the study period.
- To evaluate the clinical response rate of HBT in each arm. [ Time Frame: 13 Weeks post HBT ] [ Designated as safety issue: Yes ]
- Time to resolution of diarrhea [ Time Frame: 13 Weeks post HBT ] [ Designated as safety issue: Yes ]
- To determine the relapse rate of clinical and laboratory evidence of CDI within the 13-week study period in participants treated with fresh HBT in comparison to frozen thawed HBT. [ Time Frame: 13 Weeks post HBT ] [ Designated as safety issue: Yes ]
- Assessment of the functional health and well-being of patients [ Time Frame: Up to week 13 ] [ Designated as safety issue: No ]Patients will be asked to fill in the self-administered Health Survey at day 12, week 5, and week 13.
| Estimated Enrollment: | 136 |
| Study Start Date: | July 2012 |
| Estimated Study Completion Date: | July 2014 |
| Estimated Primary Completion Date: | March 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Fresh Human Biotherapy
Patients in this arm will receive a Fresh HBT enema. They will be followed 13 weeks to assess the cure or recurrence of CDI. All procedures across the two arms will be identical.
|
Procedure: Fresh Human Biotherapy
Patients will receive fresh fecal enema (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat HBT will be performed
Other Name: Fresh Fecal Transplantation
|
|
Experimental: Frozen-and-Thawed Human Biotherapy
Patients in this arm will receive a Frozen then Thawed HBT enema. They will be followed 13 weeks to assess the cure or recurrence of CDI. All procedures across the two arms will be identical.
|
Procedure: Frozen-and-Thawed Human Biotherapy
Patients will receive frozen-and-thawed fecal enema (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat HBT will be performed
Other Name: Frozen-and-Thawed Fecal Transplantation
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Patient inclusion criteria
- Age 18 years or older.
- Able to provide informed consent
- Laboratory or pathology- confirmed diagnosis of recurrent CDI with symptoms (defined below) within the previous 180 days.
- ≥ 2 episodes of CDI within 6 months.
Symptoms of CDI include: diarrhea defined as: 3 or more unformed bowel movements in 24 hours for a minimum of 2 days with no other causes for diarrhea
Patient exclusion criteria
- Planned or actively participating in another clinical trial.
- Patients with neutropenia with absolute neutrophil count <0.5 x 109/L
- Evidence of toxic megacolon or gastrointestinal perforation on abdominal x-ray
- Peripheral white blood cell count > 30.0 x 10E9/L AND temperature > 38.0 oC
- Active gastroenteritis due to Salmonella, Shigella, E. coli 0157H7, Yersinia or Campylobacter.
- Presence of colostomy
- Unable to tolerate HBT or enema for any reason.
- Requiring systemic antibiotic therapy for more than 7 days.
- Actively taking Saccharomyces boulardii
- Severe underlying disease such that the patient is not expected to survive for at least 30 days.
- Any condition that, in the opinion of the investigator, that the treatment may pose a health risk to the subject.
Donor inclusion
- Able to provide and sign informed consent.
- Able to complete and sign the donor questionnaire
- Able to adhere to fecal transplantation stool collection standard operating procedure.
Donor exclusion
- Tested positive for any of the following: Human Immunodeficiency virus (HIV) 1/2, hepatitis IgM, hepatitis B (HBsAg), hepatitis C antibody, syphilis, human T- lymphotrophic virus (HTLV) 1/II and vancomycin resistant Enterococcus (VRE), methicillin resistant S. aureus (MRSA), Salmonella, Shigella, E.coli O157 H7, Yersinia and Campylobacter.
- Detection of ova, parasites, C. difficile toxin, norovirus, adenovirus, rotavirus on stool examination
- History of any type of active cancer or autoimmune disease
- History of risk factors for acquisition of HIV, syphilis, Hepatitis B, Hepatitis C, prion or any neurological disease as determined by the donor questionnaire, appendix B.
- History of gastrointestinal comorbidites, e.g., inflammatory bowel disease, irritable bowel syndrome, chronic constipation or diarrhea
- Receipt of blood transfusion from a country other than Canada in preceding 6 months
- Antibiotic use or any systemic immunosuppressive agents in the 3 months prior to stool donation
- Receipt of any type of live vaccine within 3 months prior to stool donation
- Ingestion of nut or shell fish 3 days preceding donation if the recipient has known allergies to these food.
- Any current or previous medical or psychosocial condition or behaviours which in the opinion of the investigator may pose risk to the recipients or the donor
Contacts and Locations| Contact: Christine Lee, MD, FRCPC | 905 522 1155 ext 36021 | clee@mcmaster.ca |
| Contact: Jane Belanger, MSc | 905 521 6143 | jbelange@stjoes.ca |
| Canada, Ontario | |
| St. Joseph's Hospital | Recruiting |
| Hamilton, Ontario, Canada, L8N4A6 | |
| Contact: Christine Lee, MD 905 521 6021 clee@mcmaster.ca | |
| Contact: Jane Belanger, MS 905 521 6143 jbelange@stjoes.ca | |
| Principal Investigator: Christine Lee, MD, FRCPC | |
| Kingston General Hospital | Not yet recruiting |
| Kingston, Ontario, Canada, K7L2V7 | |
| Contact: Elaine Petrof, MD 6135496666 ext 6516 eop@queensu.ca | |
| Principal Investigator: Elaine Petrof, MD, MSc | |
| Principal Investigator: | Christine Lee, MD | St. Joseph's Healthcare Hamilton |
More Information
No publications provided
| Responsible Party: | Christine H. Lee, Physician, McMaster University |
| ClinicalTrials.gov Identifier: | NCT01398969 History of Changes |
| Other Study ID Numbers: | CDI.HBT.1 |
| Study First Received: | July 19, 2011 |
| Last Updated: | November 18, 2012 |
| Health Authority: | Canada: Health Canada |
Keywords provided by McMaster University:
|
Randomized Double Blind Fecal Transplant Recurrent Clostridium difficile infection CDI |
HBT Diarrhea Frozen HBT Thawed HBT Fecal Enema |
Additional relevant MeSH terms:
|
Clostridium Infections Gram-Positive Bacterial Infections Bacterial Infections |
ClinicalTrials.gov processed this record on May 23, 2013